The American Society of Hematology has named Roy L. Silverstein, MD, as its 2019 president. He will serve a year-long term through the end of December 2019.
Roy L. Silverstein, MD
Roy L. Silverstein, MD
The American Society of Hematology (ASH) has named Roy L. Silverstein, MD, as its 2019 president. He will serve a year-long term through the end of December 2019.
“Hematology is an exciting and rapidly moving discipline driven by research, innovation, and creative thinking in the clinic and in the laboratory,” said Silverstein, chairman of the department of medicine and associate director of the Medical College of Wisconsin Cancer Center. “I am delighted to serve as a leader of the organization that continues to move this field forward.”
During his presidency, Silverstein aims to develop new training programs and innovative pathways in the hematology space for clinicians and researchers. He hopes to accelerate entry into these careers.
Previously, Silverstein has served as the editor-in-chief for ASH’s news magazine,The Hematologist, chaired the Society’s Committee on Government Affairs, co-chaired the 2012 ASH Annual Meeting Scientific Program, and chaired search committees for ASH Clinical News and Blood Advances.
Silverstein is known for his research in platelet and vascular cell biology. His clinical interests include thrombosis, hemostasis, and myeloproliferative neoplasms. He also serves as a senior investigator at the Blood Research Institute at the BloodCenter of Wisconsin.
Rossetti Reviews Myelofibrosis Risk Stratification and Outcome Data for Pacritinib
July 17th 2024During a Case-Based Roundtable® event, James M. Rossetti, DO, discussed the role of risk scoring and stratification tools and treatment for a patient with declining hemoglobin and platelet counts due to primary myelofibrosis.
Read More
Phase 3 VERIFY Trial Investigates Rusfertide’s Potential in Polycythemia Vera
July 16th 2024In an interview, Aniket Bankar, MD, discussed the background, design, and goals of the phase 3 VERIFY trial of the hepcidin mimetic rusfertide for the treatment of patients with polycythemia vera.
Read More
Ruxolitinib Treatment in Myelofibrosis Still Effective, Regardless of Anemia
June 21st 2024New or worsening anemia did not appear to reduce the clinical benefit of ruxolitinib in myelofibrosis patients, and the median overall survival was similar between patients with and without new or worsening anemia.
Read More
Challenging Disease Features of Myelofibrosis Lead to Use of JAK Inhibitors
June 17th 2024During a Case-Based Roundtable® event, Kristen Pettit, MD, moderated a discussion on which disease features of myelofibrosis are most challenging and when to use JAK inhibitors in the first article of a 2-part series.
Read More